New study probes brain tumor metabolism with drug combo
NCT ID NCT05717153
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early phase trial at Mayo Clinic is studying how two drugs, DFMO and AMXT 1501, change the metabolism of brain tumors (gliomas) in 18 adult patients. The goal is to measure molecules in the tumor's fluid to understand how these drugs affect tumor growth and survival. Participants will have a biopsy or partial tumor removal, and the study focuses on learning about tumor biology, not on treating the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill slow brain tumor growth after surgery?
- Spinal fluid DNA test could personalize brain cancer therapy
- Could a nurse-led online therapy beat severe fatigue in advanced cancer?
- Experimental vaccine aims to rally immune system against recurrent brain cancer
- Immunotherapy drug nivolumab tested in young brain cancer patients
- Brain Tumor's hidden electrical signals could reveal its weaknesses